Regen Biopharma discloses full IP portfolio status with patent grants, allowances, and revival efforts

Regen BioPharma Inc

Granted US patents: BORIS gene silencing (8,263,571), NR2F6 anti-tumor methods (11,053,503), NR2F6 screening (10,088,485), NR2F6 modulation (9,091,696).
Notice of allowance received for antigen-specific mRNA cancer vaccine (app. 15/162,370).
Two patent assets in revival: siRNA cancer therapy (8,389,708) and universal donor cord blood killer cells (15/494,358).
Active applications include NR2F6 inhibition combined with cannabidiol for cancer, angiogenesis, arthritis; small molecule NR2F6 modulators.
Zander Therapeutics licensed patent for canine dendritic cell immunotherapy (10,030,227).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.